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Background: Hypertension frequently coexists with type 2 diabetes (DM), and increases the risk of cardiovascular
outcomes. The aim of the study was to obtain/maintain blood pressure (BP) goals (ADA/JNC 7) according to a
stepwise algorithm using the medication supplied by the Brazilian government.
Methods: A one-year, single-arm interventional study conducted with type 2 diabetes patients. Intervention
consisted of intensification of lifestyle changes and sequential prescription of drugs: diuretic; ACE inhibitors;
β-adrenergic blocking agent and calcium channel blocking agent if BP >130/80 mmHg.
Results: Seventy-eight patients completed the trial. During intervention, the number of antihypertensive tablets
rose (3.6 ± 3.5 vs. 5.9 ± 3.5 pills/patient; p <0.001), as the number of antihypertensive classes increased (1.8 ± 1.0 vs.
2.70 ± 1.2; p < 0.01) and the overall drop of BP was 11 mmHg for SBP (145.0 ± 22.8 vs. 133.7 ± 20.9 mmHg;
p < 0.01) and 5 mmHg for DBP (78.7 ± 11.5 vs. 73.7 ± 10.5 mmHg; p = 0.001). Although the number of patients with
BP in target almost doubled [14 (18.7%) vs. 30 (38.5%) p = 0.008], less than 40% of the patients achieved the proposed
goals.
Conclusions: A BP algorithm applied to type 2 diabetic and hypertensive patients is able to lower BP, however more
than half of the patients did not achieve the ADA/JNC 7 targets demonstrating the complexity of BP control in this
population.
Trial registration: ClinicalTrials.gov: NCT06260
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Type 2 diabetes and hypertension frequently coexist, and
patients with this combination are at a higher risk for
cardiovascular events [1]. United Kingdom Prospective
Diabetes Study (UKPDS) concluded that tight blood
pressure (BP) control in patients with type 2 diabetes and
hypertension is able to reduce micro and macrovascular
diabetic complications [2]. However, strict BP control in
this population, as advised by The Seventh Report of
the Joint National Committee on Prevention, Detection,
Evaluation and Treatment of High Blood Pressure (JNC 7)
and American Diabetes Association (ADA), with a target* Correspondence: vercoza@yahoo.com
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reproduction in any medium, provided the orBP lower than 130/80 mmHg is difficult to obtain, there-
fore multiple medications are often required [3-5].
In Brazil, hypertension was present in 81% of the
patients with diabetes participating in the HiperDia
System - a program developed to provide antihypertensive
and antidiabetic medication in primary care units through-
out the country [6]. The aim of this study was to analyze
if it is possible to obtain and maintain BP goals (ADA and
JNC 7) with an aggressive BP lowering strategy, according
to a stepwise algorithm for BP using the medication sup-
plied by the Brazilian government (HiperDia System).Patients and methods
Consecutive adult patients (greater than 18 years of age)
with type 2 diabetes, who were regularly attending a pri-
mary care unit (at least 2 consultation in the last during
the 6-month period before the screening visit), weretd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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history of active infection (eg. osteomyelitis, pulmonary
tuberculosis, AIDS), chronic corticosteroids use, unstable
angina or myocardial infarction in the last 3 months, ad-
vanced renal disease – defined as dialysis procedures, se-
vere heart failure (classes 3 and 4), cirrhosis, alcohol or
illicit drug use, dementia or difficult to full understand
the studies procedures, current pregnancy or lactation,
current cancer or any disease that might affect survival in
the next 5 years.
At baseline, patients underwent an evaluation consisting
of history and physical examination. Patients were consid-
ered as smokers or non-smokers. Ethnic definition was
self-classified as white or non-white. Previous medical his-
tory was evaluated clinically. Cerebrovascular disease was
established in the presence of a history of stroke and/or
compatible findings (sequelae). The diagnosis of heart
disease was based on a previous history of myocardial in-
farction, angina or heart failure and when available myo-
cardial scintigraphy and coronary angiography. Body mass
index (BMI) was calculated [weight (kg)/height2 (m)].
Blood pressure (BP) was measured twice at each visit in
the sitting position after 10 minutes rest with OMRON
Automatic Blood Pressure Monitor HEM- 720. Hyperten-
sion was defined as blood pressure levels ≥140/90 mmHg
or use of anti-hypertensive drugs at screening visit. The
protocol was approved by the Ethics Committee of
Hospital de Clínicas de Porto Alegre and all patients
provided written informed consent. This protocol was
registered in Clinical Trials (ID 06260).
Study design and interventions
This one-year, open-label, non-controlled, single-arm
interventional study was conducted at a primary care
unit located off-campus but in association with Hospital
de Clínicas de Porto Alegre, a university hospital, in the
metropolitan area of the city of Porto Alegre, Brazil.
This unit is responsible for health care of approximately
40.000 individuals. Patients attending the primary care
unit with diabetes and hypertension were invited to join
the study.
The study comprised 3 stages: a run-in (3 months),
drug intervention period (6 months) and stabilization
period (2–3 months) and was conducted by an endo-
crinologist (LVV) and a generalist nurse (MFG). During
the run-in period, patients were advised to maintain a
healthy diet, to exercise and to take all the medications
prescribed by their primary care physicians. Patients vis-
ited the primary care unit monthly and received orienta-
tion about diet, exercise and adherence to medication
already in use. During the intervention period, partici-
pants visited the center at monthly intervals to check
weight, BP, and glucose. The goal was to obtain systolic
and diastolic BP ≤130/80 mmHg. If the mean systolic ordiastolic BP values were higher than 130/80 mmHg, medi-
cations were administered in the following sequence: diur-
etic (hydrochlorothiazide); angiotensin converting enzyme
(ACE) inhibitors (captopril or enalapril); β-adrenergic
blocking agent (propranolol) and calcium channel blocking
agent (amlopidine). These drugs are provided by the
Brazilian public health care system. Medications were
available at the primary care unit and patient was
able to take it just after the consultation. The patients
requiring more than four antihypertensive medications
used hydralazine and/or clonidine (not available in
the primary care unit). Medication was started with
the lowest dose recommended by the manufacturer,
and increased in increments until the maximum toler-
ated dose at monthly intervals guided by BP measure-
ments. Another class of antihypertensive drugs was added
after the maximum tolerated dose was reached. During
the study period, patients received standard medical care
in the primary care unit for intercurrences or other con-
comitant illness.
Endpoints
Study endpoints were the change in systolic and diastolic
BP after the intervention as well as the proportion of pa-
tients reaching and maintaining a BP ≤130/80 mmHg
during the one-year study period.
Laboratory methods
Fasting plasma glucose was measured by the glucose
oxidase ultraviolet (UV) enzymatic method. Total chol-
esterol, HDL and triglycerides were measured by enzym-
atic methods. Low-density lipoprotein cholesterol (LDL)
was calculated using the Friedewald equation. Serum cre-
atinine was measured by a kinetic alkaline picrate method
(Jaffe reaction) and converted to the standardized Jaffe
Roche (CREA), traceable method, by linear regression
equation (traceable Jaffe creatinine = − 0.236 + 1.061 ×
uncompensated Jaffe creatinine). Urinary albumin was
measured in duplicate by immunoturbidimetric method
(Microalb; Ames-Bayer, Tarrytown NY). Microalbuminuria
was defined by a random spot urine sample higher
than 17 mg/l [7,8]. All chemistry parameters were an-
alyzed in a Modular P (Roche® (Basel, Switzerland). The
HbA1c test measurements (%) were performed by HPLC.
Statistical analysis
Results are expressed as mean ± SD, median (P25-P75)
or number of cases with the characteristic (%). Compari-
sons were performed by Student’s t test, Mann–Whitney
U test or Chi-square test, as appropriate. Paired t-test
was used to compare BP variation before and after inter-
vention. P values <0.05 (two-sided) were considered
to be statistically significant. SPSS 18.0 - Professional
Statistics™ (SPSS Inc., Chicago, IL, USA) was used.
Table 1 Baseline clinical and laboratory characteristics of
107 hypertensive type 2 diabetic patients
Baseline
N 107
Age (years) 62.6 ± 11.2
White ethnicity – n (%) 88 (82.2%)
Female sex– n (%) 69 (64.5%)
Diabetes duration (years) 8.3 ± 9.2
Primary care unit attendance (years) 2.3 ± 2.7
Previous cardiovascular event – n (%) 21 (19.2%)
Current Smoking – n (%) 9 (8.4%)
SBP (mmHg) 145.3 ± 21.6
DBP (mmHg) 79.0 ± 11.4
BMI (kg/m2) 30.2 ± 5.9
Using statin – n (%) 47 (44%)
Using aspirin– n (%) 66 (61.8%)
Microalbuminuria– n (%) 25 (23.4%)
Diabetes Treatment - n (%)
Diet only 11 (10.3%)
One agent 46 (43%)
Two agents 42 (39.2)
Three agents 8 (7.5%)
Insulin use 23 (21.5%)
Hypertension Treatment
No drugs 11 (10.3%)
One agent 28 (26.2%)
Two agents 46 (43%)
Three agents 16 (15%)




Calcium channel blocking 15
Total cholesterol (mg/dl) 179.9 ± 39.7
HDL cholesterol (mg/dl) 48.0 ± 11.3
Triglycerides (mg/dl) 152 (107.3 -368.7)
LDL cholesterol (mg/dl) 100.6 ± 28.4
HbA1c (%) 7.3 ± 1.6
Data are mean ± SD, number of patients with the characteristic (%).
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Baseline characteristics
The original cohort comprised 116 diabetic patients of
which 107 (92%) were diagnosed with hypertension.
Mean hypertension duration was 10.7 ±10.4 years. The
baseline characteristics of the hypertensive patients are
shown in Table 1. Most patients were white (82.2%), 9
(8.4%) patients were smokers, and the mean BMI was
30.2 ± 5.9 kg/m2. At enrollment, diabetes treatment was
diet alone in 11 patients, one oral agent in 46, two oral
agents in 42, and three medications in 8; insulin was
used in 23 (4 patients on insulin alone). Forty-four per-
cent of the patients were on statins and mean LDL was
100.6 ± 28.4 mg/dl. Twenty-one patients (19.2%) had a
previous cardiovascular event (stroke n = 4; ischemic heart
disease n = 17; heart failure n = 3; lower limb amputation
n = 1) and 25 patients (23.4%) were microalbuminuric.
Mean systolic BP (SBP) and diastolic BP (DBP) were
145.3 ± 21.6 mmHg and 79.0 ± 11.4 mmHg, respect-
ively, and BP lower than 130/80 mmHg was observed
in 16 (15%) patients at the first visit. Hypertension
medication previously prescribed by a primary care
physician was as follows: no medication in 11 (10.3%)
patients; one agent in 28 (26.2%); two agents in 46
(43%); three agents in 16 (15%) and four agents in 6
(5.5%) (69 patients on diuretics, 76 on ACE inhibitor,
36 on beta-blocker agent and 15 patients were using
calcium channel blocking agents).
Follow-up results
Of the 107 hypertensive patients that agreed to partici-
pate in the study, 29 (27%) were lost to follow-up and
were not included in the final analysis [withdrawal of
consent form (n = 3), lost to follow-up (n = 19), death
(n = 2), stroke with important physical limitation (n = 1),
and cancer (n = 4)]. Therefore, the results of the 78 pa-
tients (73%) that completed the trial are presented below.
There was no difference between missing patients and
those who completed the follow-up regarding age, sex,
duration of hypertension and diabetes, and BP levels.
Changes in blood pressure are shown in Figure 1.
From baseline to the end of the run-in period, there was
a significant reduction in both systolic (145.0 ± 22.8 vs.
138.8 ± 21.2 mmHg; p = 0.002) and diastolic BP (79.4 ±
11.5 vs. 76.5 ±10.9; p = 0.026), yet no increase in the
number of pills taken in this first part of the study was
observed (3.4 ± 3.5 vs. 3.8 ± 3.5; p = 0.137). In the inter-
vention period, the number of antihypertensive tablets
increased (3.6 ± 3.5 vs. 5.9 ± 3.5 pills/patient; p <0.001),
as the number of antihypertensive classes increased
(1.8 ± 1.0 vs. 2.70 ± 1.2; p < 0.01). During this period, a
further decline in SBP and DBP was observed and
the overall drop of BP was 11 mm Hg for SBP (145.0 ±
22.8 vs. 133.7 ± 20.9 mmHg; p < 0.01) and 5 mmHg forDBP (78.7 ± 11.5 vs. 73.7 ± 10.5 mmHg; p = 0.001); the
number of patients with BP values lower than 130/80
mmHg almost doubled [14 (18.7%) vs. 30 (38.5%) p =
0.008] from the first visit to the end of the study. During
the stabilization period there was neither a decline in
BP nor an increase in medication taken.
In order to identify baseline characteristics associated






Figure 1 Blood Pressure decrease and Medication Tablets increase throughout the study: Panel A – Systolic Blood Pressure (mean ± SE);
*Run-In: Systolic BP: 145.0 ± 22.8 vs. 138.8 ± 21.2 mmHg; p = 0.002; ** Intervention Systolic BP: 138.5 ± 21.21 to 132.6 ± 14.8 mmHg;
P = 0.046; Panel B – Diastolic Blood Pressure (mean ± SE). +Run-In: Diastolic BP: 79.4 ± 11.5 vs. 76.5 ± 10.9; p = 0.026; ++ Intervention Diastolic
BP: 76.4 ± 11.05 to 74.4 ± 8.6; P <0.01.
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differences regarding age, gender, and hypertension dur-
ation were seen between patients reaching BP goals, with
the exception of a higher SBP at baseline in those with
BP higher than 130 mmHg at the end of the study.
Conclusion
In this cohort of type 2 diabetic and hypertensive pa-
tients, mean initial BP was 145/79 mmHg and only 15%
of patients had ADA and JNC 7 target BP levels.
During this one-year study, the number of patients
who achieved the goal increased to 39%, with a mean
drop of 11 mmHg in the SBP and 5 mmHg in DBP.
The end-of-study BP was ~134/74 mmHg due to an
important increase in the number of pills taken by
these patients. It is worth noting that less than half
the study participants ended the follow-up with a BP
<130/80 mmHg.
Our baseline data is in agreement with previous results
from a cross-sectional study conducted in Porto Alegre,
Brazil, where 83% of the treated patients had BP levels
higher than ADA goals [5]. A survey of NCHS examined
hypertension management in diabetic patients and dem-
onstrated that 66% of the diabetic patients visitingoutpatient clinics had BP higher than the goals, with
a mean of 139/78 mmHg. Interestingly, 71% of these pa-
tients were using antihypertensive agents, with nearly half
involving prescription of 2 or more medications [9].
Therapeutic inertia is an important factor contributing
to persistent elevated BP in these patients. In a cross-
sectional study, researchers from Colorado found that
more than 60% of type 2 diabetic patients did not achieve
blood pressure goals, and actions to lower BP were taken
in only 35% of the cases [10]. In our study, an aggressive
BP lowering strategy, consisting of monthly evaluations
and forced medication titration, doubled the number of
patients with BP below the target. Two other strategies
were tested in recently published trials to control BP in
diabetic populations [11,12]. The addition of a pharmacist
and a nurse to manage the patients cardiovascular risks in
primary care resulted in BP reductions similar to those
observed in the present study [11,12].
Another important factor that could contribute to the
low number of patients on target is patient’s non-adherence
to lifestyle modification strategies. The decrease in BP ob-
served in the run-in period probably reflects an improve-
ment in patient’s adherence to behavior modification
reinforcements (lifestyle intervention) in the first 3 months
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out the study despite orientation about diet and exercise at
each appointment. Modifying diabetic patients diet is
another important way to reduce BP. DASH diet ap-
plied to a diabetic population was able to reduce both
systolic BP and diastolic blood pressure (−13.6 ± 3.5
mmHg; -9.5 ± 2.6 mmHg, respectively) [13].
Recently, BP targets in patients with diabetes and
hypertension have been debated [14,15] because only one
intervention study testing different BP goals was able to
lower patients BP levels to ADA and JNC 7 recommenda-
tions [16]. In this scenario, a less strict blood pressure
control (BP <140/80 mmHg or between 130-135 mmHg)
as suggested by a recent meta-analysis [17] may be consid-
ered a more adequate target. Even when analyzed from
this perspective (BP <140/80 mmHg) which matches the
new recommendation from ADA 2013 [18], only 31%
of our patients were initially well controlled and after
the study intervention this number increased to 54%,
leaving 46% of the patients at a higher risk for diabetic
complications.
In conclusion, a BP algorithm applied to type 2 diabetic
and hypertensive patients is able to lower BP, however
more than half of the patients did not achieve the ADA
and JNC 7 targets, demonstrating the complexity of BP
control in this population. Revision of antihypertensive
treatment strategies, perhaps employing a more aggressive
life-style intensification strategy and/or including new
classes of agents, is needed in order to guarantee an ad-
equate BP control in patients with type 2 diabetes.
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